【レポートの概要（一部）】
1 Chapter 1: Introduction
1.1 Executive Summary
1.2 Topics Covered
1.3 Historical Revenue & Forecast Segmentation
1.4 Key Questions Answered
1.5 Key Findings
1.6 Methodology
1.7 Target Audience
1.8 Companies & Organizations Mentioned
2 Chapter 2: An Overview of Generic Drugs
2.1 What is a Generic Drug?
2.2 Reserve Engineering: How Are Generics Conceived?
2.3 The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs?
2.3.1 What Defines Bioequivalence?
2.3.2 Acceptable Bioequivalence Ranges
2.4 The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts?
2.5 Economics: Price Comparison
2.6 Brand Classification: Pure vs. Branded Generics
2.6.1 Pure (Non-branded) Generics
2.6.2 Branded Generics
2.6.3 Super Generics
2.7 Market Growth Drivers
2.7.1 Cost Effectiveness and Affordability
2.7.2 Low Insurance Premiums
2.7.3 Patent Expiry of Innovator Drugs
2.7.4 Political & Regulatory Support
2.7.5 Global Proliferation & Increasing Demand
2.8 Market Barriers
2.8.1 Patent Linkage: Delaying Product Launch
2.8.2 Complex Product Portfolios
2.8.3 Quality Control Issues
2.8.4 Intense Competitive Landscape
2.8.5 Resistance from Big Pharma Players
3 Chapter 3: Regulatory Landscape
3.1 Regional Outlook
3.1.1 Asia Pacific
3.1.2 Europe
3.1.3 Middle East & Africa
3.1.4 Latin & Central America
3.1.5 North America
3.2 International Initiatives
3.2.1 WHO Guidelines
3.2.2 IGDRP (International Generic Drug Regulators Pilot)
3.2.3 EMA (European Medicines Agency): Extending Collaboration beyond the EU
4 Chapter 4: Drug Class Availability & Leading Therapies
4.1 Drug Class Availability
4.1.1 Antibiotics
4.1.2 Cardiovascular & Hypertension
4.1.3 CNS (Central Nervous System)
4.1.4 Dermatology
4.1.5 Diabetes
4.1.6 Gastrointestinal
4.1.7 Hormonal Drugs
4.1.8 Onocology
4.1.9 Pain Relief
4.1.10 Respiratory
4.1.11 Rheumatology
4.1.12 Other Categories
4.2 Leading Generic Drugs
4.2.1 Acetaminophen (Paracetamol)
4.2.2 Alprazolam
4.2.3 Amlodipine
4.2.4 Amoxicillin
4.2.5 Asprin (Acetylsalicylic Acid)
4.2.6 Atenolol
4.2.7 Atorvastatin
4.2.8 Azithromycin
4.2.9 Bendroflumethiazide
4.2.10 Betamethasone Dipropionate
4.2.11 Candesartan
4.2.12 Clavulanic Acid
4.2.13 Clopidogrel
4.2.14 Dexamfetamine
4.2.15 Diclofenac
4.2.16 Doxycycline
4.2.17 Enalapril
4.2.18 Enoxaparin Sodium
4.2.19 Esomeprazole
4.2.20 Fentanyl
4.2.21 Fenofibrate
4.2.22 HCTZ (Hydrochlorothiazide)
4.2.23 Ibuprofen
4.2.24 Lansoprazole
4.2.25 Levothyroxine Sodium
4.2.26 Lisinopril
4.2.27 Losartan
4.2.28 Metformin
4.2.29 Methylphenidate
4.2.30 Methotrexate
4.2.31 Metoprolol
4.2.32 Omeprazole
4.2.33 Pantoprazole
4.2.34 Perindopril
4.2.35 Ramipril
4.2.36 Rosuvastatin
4.2.37 Salbutamol (Albuterol)
4.2.38 Simvastatin
4.2.39 Valsartan
4.2.40 Venlafaxine
4.2.41 Others
5 Chapter 5: Generic Drugs Industry Roadmap & Value Chain
5.1 Industry Roadmap
5.1.1 2015 – 2020: Overtaking Innovator Drugs
5.1.2 2020 – 2025: The Era of Generic Biologics
5.1.3 2025 – 2030 & Beyond: Evolving Regulatory Landscape
5.2 Value Chain
5.2.1 API Manufacturers & Enabling Technology Providers
5.2.1 Generic Drug Manufacturers
5.2.2 Innovator Pharmaceutical Companies
5.2.3 Regional Distributors
5.2.4 Healthcare Providers, Pharmacies & Drug Stores
6 Chapter 6: Key Market Players
6.1 Abbott Laboratories
6.2 AbbVie
6.3 ACETO Corporation
6.4 Acino Holding
6.5 Actavis
6.6 Actelion
6.7 Adcock Ingram
6.8 Ajinomoto
6.9 Akron
6.10 Alexion Pharmaceuticals
6.11 Alfa Wasserman
6.12 Amgen
6.13 AMRI (Albany Molecular Research, Inc.)
6.14 Amneal Pharmaceuticals
6.15 Apotex
6.16 ASKA Pharmaceutical Company
6.17 Aspen Holdings
6.18 Astellas Pharma
6.19 AstraZeneca
6.20 Aurobindo Pharma
6.21 Baxter BioScience
6.22 Bayer AG
6.23 BD (Becton, Dickinson and Company)
6.24 Biogen Idec
6.25 Biocon
6.26 Boehringer Ingelheim
6.27 BMS (Bristol-Myers Squibb)
6.28 Cadila Healthcare (Zydus Cadila)
6.29 Cadila Pharmaceuticals
6.30 Celgene Corporation
6.31 Chiesi Farmaceutici
6.32 Chugai Pharmaceutical Company
6.33 Claris Lifesciences
6.34 Cipla
6.35 Coherus BioSciences
6.36 Consort Medical
6.37 Daiichi Sankyo
6.38 Dong-A Pharmaceutical
6.39 Dr. Reddy’s Laboratories
6.40 Eisai Company
6.41 Eli Lilly and Company
6.42 Endo International
6.43 ESTEVE Group
6.44 Eurofarma Laboratorios
6.45 Ferring Pharmaceuticals
6.46 Fresenius Kabi
6.47 Fujifilm Pharma Company
6.48 Fuji Pharma Company
6.49 Galderma
6.50 Galenika
6.51 Gedeon Richter
6.52 Genepharm
6.53 Gilead Sciences
6.54 Glenmark Pharmaceuticals
6.55 Grifols
6.56 Gruenenthal Group
6.57 GSK (GlaxoSmithKline)
6.58 Hanmi Pharmaceutical Company
6.59 Hetero Drugs
6.60 Hikma Pharmaceuticals
6.61 Hospira
6.62 Impax Laboratories
6.63 Ipsen
6.64 JT (Japan Tobacco)
6.65 Jazz Pharmaceuticals
6.66 Johnson & Johnson
6.67 Kaken Pharmaceutical Company
6.68 Kaneka Corporation
6.69 Kowa Company
6.70 Kremers Urban Pharmaceuticals
6.71 Krka (Krka, d. d.)
6.72 Kyowa Hakko Kirin Company
6.73 Laboratorios Roemmers
6.74 Leo Pharma
6.75 Les Laboratoires Servier
6.76 Lundbeck (H. Lundbeck A/S)
6.77 Lupin
6.78 Mallinckrodt
6.79 Maruho Company
6.80 Meda
6.81 Meiji Holdings
6.82 Menarini Group
6.83 Merck and Co.
6.84 Merck KGaA
6.85 Merz Pharma
6.86 Mitsubishi Tanabe Pharma
6.87 Mitsui & Company
6.88 Mylan
6.89 Natco Pharma
6.90 Nichi-Iko Pharmaceutical Company
6.91 Nippon Kayaku
6.92 Nippon Shinyaku
6.93 Nipro Pharma Corporation
6.94 Novo Nordisk
6.95 Ono Pharmaceutical Company
6.96 Orion Corporation
6.97 Otsuka Holdings Company
6.98 Par Pharmaceutical Companies
6.99 Perrigo Company
6.100 Pfizer
6.101 Pharmstandard
6.102 Pierre Fabre (Laboratoires Pierre Fabre)
6.103 Piramal Enterprises
6.104 Pliva (Pliva d.d.)
6.105 Prasco Laboratories
6.106 Purdue Pharma
6.107 Ranbaxy Laboratories
6.108 Recordati
6.109 Regeneron Pharmaceuticals
6.110 Roche Holding (F. Hoffmann-La Roche)
6.111 Salix Pharmaceuticals
6.112 Samsung Group
6.113 Sandoz International (Novartis International)
6.114 Sanofi
6.115 Santen Pharmaceutical Company
6.116 Sawai Pharmaceutical Company
6.117 Seikagaku Corporation
6.118 Sequent Scientific
6.119 Shionogi & Company
6.120 Shire
6.121 Sigma-Tau
6.122 STADA Arzneimittel
6.123 Strides Arcolab
6.124 Sumitomo Dainippon Pharma Company
6.125 Sun Pharmaceutical Industries
6.126 Taisho Pharmaceutical Holdings Company
6.127 Takeda Pharmaceutical Company
6.128 Teijin
6.129 Teva Pharmaceutical Industries
6.130 The Medicines Company
6.131 Torrent Pharmaceuticals
6.132 Towa Pharmaceutical Company
6.133 UCB
6.134 United Therapeutics Corporation
6.135 Valeant Pharmaceuticals International
6.136 Vertex Pharmaceuticals
6.137 Wockhardt
7 Chapter 7: Market Analysis & Forecasts
7.1 Global Outlook of Generic Drugs
7.2 Segmentation by Brand Classification
7.2.1 Pure (Non-branded) Generics
7.2.2 Branded Generics
7.2.3 Super Generics
7.3 Segmentation by Therapeutic Area
7.3.1 Antibiotics
7.3.2 Cardiovascular & Hypertension
7.3.3 CNS
7.3.4 Dermatology
7.3.5 Diabetes
7.3.6 Gastrointestinal
7.3.7 Hormonal Drugs
7.3.8 Oncology
7.3.9 Pain Relief
7.3.10 Respiratory
7.3.11 Rheumatology
7.3.12 Others
7.4 Segmentation by Region
7.4.1 Asia Pacific
7.4.2 Europe
7.4.3 Middle East & Africa
7.4.4 Latin & Central America
7.4.5 North America
7.5 Top Country Markets
7.5.1 Brazil
7.5.2 Canada
7.5.3 China
7.5.4 Egypt
7.5.5 France
7.5.6 Germany
7.5.7 Greece
7.5.8 India
7.5.9 Israel
7.5.10 Italy
7.5.11 Japan
7.5.12 Mexico
7.5.13 Netherlands
7.5.14 Poland
7.5.15 Portugal
7.5.16 Russia
7.5.17 Saudi Arabia
7.5.18 South Africa
7.5.19 South Korea
7.5.20 Spain
7.5.21 Switzerland
7.5.22 Taiwan
7.5.23 Turkey
7.5.24 UK
7.5.25 USA
8 Chapter 8: Conclusion & Strategic Recommendations
8.1 Why is the Market Poised to Grow?
8.2 Are Generic Drugs Becoming Expensive?
8.3 Competitive Industry Landscape: Acquisitions, Alliances & Consolidation
8.4 High Profile Recalls: What is the Impact on the Market?
8.5 Lower-Cost Countries: Increasing R&D and Manufacturing Investments
8.6 Geographic Outlook: Which Countries Offer the Highest Growth Potential?
8.7 Prospects of Biosimilars
8.7.1 How Big is the Biosimilars Opportunity?
8.7.2 Regulatory Status
8.8 Strategic Recommendations
8.8.1 Generic Drug Manufacturers
8.8.2 Innovators
【レポート販売概要】
■ タイトル：後発医薬品の世界市場：機会、課題、戦略、市場予測■ 英文：The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts
■ 発行日：2015年2月
■ 調査会社：Signals and Systems Telecom
■ 商品コード：DATA5022408
■ 調査対象地域：グローバル
- ラクロス用品の世界市場2017-2021About Lacrosse Equipment Lacrosse is a team sport in which players try to score points by getting a rubber ball into a long lacrosse stick with a net. They run, carry, catch, shoot, and pass the ball with the net of the stick, just to finally reach the goal. Lacrosse has many benefits associated with it in terms of exercise and competitiveness as the game involves a lot of running, speed, and endu …
- ガラス製包装容器（パッケージ）の世界市場2015-2019About glass packaging Glass packaging is used in the packaging of F&B, pharmaceuticals, chemicals, and cosmetics. Glass bottles and jars can be molded into a variety of shapes and dimensions. Its inert nature and ability to preserve products over a long period of time makes glass a popular choice for packaging in the F&B industry. Glass provides the aesthetic appeal required for certain products t …
- 2014年戦略提言：アメリカの止血診断検査市場Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.SummaryThis comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the next five years. The report explores business and technologic …
- マルチクラウド管理の世界市場予測（～2022年）Avoidance of vendor lock-ins, increased agility and automation, and the need for a high-level of governance and policy are expected to be driving the multi-cloud management marketThe multi-cloud management market size is expected to grow from USD 1,169.5 million in 2017 to USD 4,492.7 million by 2022, at a Compound Annual Growth Rate (CAGR) of 30.9% during the forecast period. The multi-cloud mana …
- OTCブレース及びサポートの世界市場予測（～2024年）“The OTC braces and supports market is projected to grow at a CAGR of 5.1% during the forecast period” The OTC braces and supports market is projected to reach USD 1.5 billion by 2024 from USD 1.2 billion in 2019, at a CAGR of 5.1%. The growth in this market is majorly driven by the increasing prevalence of orthopedic diseases & disorders, rising number of sports and accident-related injuries, and …
- 沈降シリカの世界市場2017-2021About Precipitated SilicaPrecipitated silica is commonly produced by the precipitation of sodium silicate with sulfuric acid and hydrochloric acid. Precipitated silica is mainly used in different applications such as rubber, agrochemicals, personal care, food and feed, and others. In coatings and inks, precipitated silica is an economical substitute for titanium dioxide. Precipitated silica is pre …
- Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust GrowthMonoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth Summary GBI Research has released the pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), …
- スタジアム照明の世界市場予測（～2023年）“Enhancing stadium experiences of fans using LEDs to drive growth of stadium lighting market”The stadium lighting market is expected to reach USD 622.2 million by 2023 from USD 432.0 million in 2018, at a CAGR of 7.57% between 2018 and 2023. Factors such as upcoming national and international sports events, enhanced stadium experiences of fans using LEDs, and reducing costs of LEDs and lifecycle o …
- 世界のライトタワー市場：市場種類別（販売、レンタル）、ライト種類別（メタルハライドおよびLED）、燃料種類別（ディーゼル、ソーラー/ハイブリッドおよび直接電力）、エンドユーザー別（石油＆ガス、鉱業、建設、イベント＆スポーツ）、地域別“The global light towers market size is expected to reach USD 6.1 billion by 2024, at a CAGR of 5.5% from 2019 to 2024” The global light towers market size is projected to reach USD 6.1 billion by 2024 from estimated revenue of USD 4.7 billion in 2019, at a CAGR of 5.5% during the forecast period. The factors driving the market include increasing investment in oil & gas and construction infrastruc …
- モバイルインサイト：Mobile InsightsThe Mobile Insights market research subscription service provides critical analysis for the mobile and wireless needs of today’s highly mobile enterprise and includes the following: ■ Mobile Letter (weekly). Mobile Letter provides insights about hot mobile and wireless topics. Published weekly on Wednesdays and primarily written by J. Gerry Purdy, Ph.D., who is known for his insights beyond the ne …
- クラウドセキュリティのグローバル市場動向（2014-2020）Cloud Security is a strong growing market. This market witnessed the growth, particularly after 2010, when majority of organizations started adopting cloud services for cost cutting, agility and flexibility of IT infrastructure. Also, this era experienced the emergence of cloud specific threats. Hence to balance the migration to cloud services without compromising security led to adoption of cloud …
- 癌性疼痛(Cancer Pain)：世界の治験レビュー（2015年上半期版）Cancer Pain Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, H1, 2015" provides an overview of Cancer Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Cancer Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted acro …
- 生体触媒作用・生体触媒の世界市場2016-2020About Biocatalysis and Biocatalysts Biocatalysis is a chemical process in which enzymes and other biological catalysts are used to speed up the reaction between organic components. These enzymes are derived from microorganisms or plant and animal cells. The use and penetration of biocatalysts are increasing in industries, such as agriculture and feed, textile, biofuel production, and biopharmaceut …
- 世界の深海/超深海開発（E&P）市場：地震、掘削、海底及びFPS技術The global market for deepwater & ultra deepwater E&P spending is set to reach $66.25bn in 2014, with spending in the seismic, drilling, subsea and FPS submarkets all promising strong growth prospects. Although some delay has been recognised in the market as project costs continue to escalate, and financing has become more challenging, the overriding demand for increased oil & gas production is se …
- ガス絶縁変圧器の世界市場予測（～2023年）“The gas insulated transformer market is expected to grow at a CAGR of 4.61% from 2018 to 2023” The gas insulated transformer market is expected to grow from USD 2.75 billion in 2018 to USD 3.45 billion by 2023, at a CAGR of 4.61%. Gas insulated transformers are oil-free, nonflammable, and nonexplosive. These transformers use SF6 gas as the cooling and insulating medium, and are preferred over oil …
